Positive Correlation of Hyams Histopathologic Grading in Esthesioneuroblastoma to PET/CT Enhancement and Survival Rates

Arffa, Rachel E.; Caballero, Nadieska; Lanza, Donald C.; Solyar, Alla; Rourke, Adam; Davis, K. C.

doi:10.1055/s-0036-1579793

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Имеется корреляция величины стандартизированного коэффициента максимального поглощения при ПЭТ/КТ с 18F-фтордезоксиглюкозой в зависимости от гистопатологической классификации Hyam и при развитии рецидивов [29].…”

Section: Original Articleunclassified

Esthesioneyroblastoma. Retrospective analysis of 10 observations

Огнерубов

Antipova²,

Ognerubova³

2022

Consilium Medicum

View full text Add to dashboard Cite

Background. Esthesioneyroblastoma is a rare malignant tumor arising from olfactory neuroepithelium of the nasal cavity. It is an aggressive local tumor. It accounts for 3 to 6% of cases of nasal and sinus cancer. Occurs at any age. Due to the rarity of the disease, there are no uniform standards of treatment. A multimodal and interdisciplinary approach is recommended. Aim. To present the results of a retrospective study of patients with esthesioneuroblastoma. Materials and methods. The retrospective study was carried out using the database of departments of radionuclide diagnostics of Nuclear Medicine Centres from 2012 to 2022. Ten patients with histologically confirmed diagnosis of esthesioneyroblastoma were identified. Results. Age of patients from 29 to 67 years, median 51 years. Men and women equal. The clinical picture was dominated by a sense of nasal congestion and various nose impairments 8 and 7 patients. The tumor was more often confined to the left side of the nose. Computer tomography (CT), magnetic resonance imaging and positron emission tomography combined with CT (PET/CT) were used for diagnosis, estimation of tumor process prevalence and outpatient observation. Stage A by Kadish was identified in 2 cases, and stage B in 1 patient. Stage C 6 patients predominated. D was diagnosed in 1 patient. The use of PET/CT clarifies the primary stage, the effect of therapy, provides disease control during dynamic observation. The SUVmax median for primary tumor was 7.43 (4.319.1). A multi-modal approach is used to treat esthesioneuroblastoma. The surgical method is performed by 4 patients with subsequent radiation therapy. Radiation therapy was carried out at the first stage of 3 patients, the total focal dose was 66 Gy. Polychemotherapy followed by radiotherapy was used in 3 cases. Duration of observation ranged from 8 to 108 months, median 47.5 months. Conclusion. Esthesioneyroblastoma is a rare malignant nasal tumor. The peak of the disease falls on 5070 years. No gender differences have been identified. The main clinical symptoms are nasal congestion 8 patients and various smelling disorders 7 patients. PET/CT is the main imaging method in the diagnostic, evaluation and observation phases. In this case, most often (6 patients) is determined stage C by Kadish.

show abstract

Section: Original Articleunclassified